

From: [Janice Castillo](#)
To: [Gildner, Jean](#)
Subject: RE: BLA 125586 Information Request
Date: Wednesday, January 03, 2018 3:29:41 PM
Attachments: [image007.png](#)

Receipt acknowledged.

From: Gildner, Jean [mailto:Jean.Gildner@fda.hhs.gov]
Sent: Wednesday, January 03, 2018 12:21 PM
To: Janice Castillo
Subject: BLA 125586 Information Request

Dear Janice,

A review of the submission from January 2, 2018, shows that Portola's submission from 12/1/17 does not include data (ADAE) for the six subjects listed. In addition, the request is to update all adverse events based on investigator assessment for the 185 subjects.

Submission of a text document or adjudication dossier does not satisfy the request to update the ADAE table, since the analysis tables (ADAE) in this case is used for our analysis. Missing data from the six subjects and investigator assessed AEs are not included in the ADAE dataset.

Therefore, providing an pdf document does not facilitate analysis that the clinical reviewer performs.

Therefore the request from 12/21 remains incomplete. Please provide the ADAE dataset as requested by **tomorrow 12 noon EST**.

Please acknowledge receipt of this email.

Sincerely, Jean

Jean F. Gildner MSHS, MT (ASCP)
Regulatory Project Manager
Center for Biologics Evaluation and Research
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration
Tel: 240-402-8296
jean.gildner@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM

IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message. If you are the intended recipient, please be advised that the content of this message is subject to access, review and disclosure by the sender's Email System Administrator.